Enzymopenic hereditary methemoglobinemia: a clinical/biochemical classification

Area of Science:

• Biochemistry
• Genetics
• Clinical Medicine

Background:

• NADH-cytochrome B5 reductase deficiency is a recessively inherited disorder.
• The clinical presentation varies based on the mutation's effect on the enzyme's activity and cellular distribution.
• Previous classifications have recognized different types of this deficiency.

Purpose of the Study:

• To summarize observations supporting a clinical and biochemical classification of enzymopenic hereditary methemoglobinemia.
• To differentiate between various types of NADH-cytochrome B5 reductase deficiency.

Main Methods:

• Review and synthesis of existing clinical and biochemical data.
• Classification based on enzyme deficiency location (erythrocytes, generalized, hematopoietic cells) and cofactor status.
• Genetic analysis linking mutations to chromosome 22.

Main Results:

• Type I: Erythrocyte-specific deficiency, presenting as benign methemoglobinemia.
• Type II: Generalized deficiency with severe neurological disability and methemoglobinemia.
• Type III: Hematopoietic cell deficiency, clinically similar to Type I.
• Type IV: Cofactor (cytochrome B5) deficiency, also clinically similar to Type I.

Conclusions:

• NADH-cytochrome B5 reductase deficiency leads to diverse clinical outcomes.
• Mutations in a gene on chromosome 22 are implicated in most types, affecting enzyme function.
• A clear classification aids in understanding the disease spectrum and prognosis.